TNF and infection: Moreover, the interaction between anti-TNF drugs and the capacity to develop immunity at mucocutaneous sites following breakthrough infection may be an important aspect to tackle, in and beyond the context of SARS-CoV-2, as barrier site immunity has been shown to develop in individuals with SARS-CoV-2 hybrid immunity [34,35] and is perhaps linked to improved outcomes against pathogens.